基于模型的预测,在瘤学中使用组合疗法的无进展生存率
Marcus Baaz1,2, Tim Cardilin1, Mats Jirstrand1
1Fraunhofer-Chalmers Research Centre for Industrial Mathematics, Gothenburg, Sweden.
CPT: pharmacometrics & systems pharmacology
|June 10, 2023
概括
这项研究开发了一种联合模型,用于预测转移性结直肠癌患者的无进展生存期 (PFS). 该模型准确地描述了瘤大小和PFS,有助于临床试验设计和药物开发.
科学领域:
- 在瘤学瘤学.
- 制药指标 (Pharmacometrics) 是一个指标.
- 临床试验分析
背景情况:
- 无进展生存率 (PFS) 是瘤学临床试验中的一个关键指标.
- 目前用于PFS分析的方法通常是描述性的 (例如,Kaplan-Meier估计器).
- 预测建模需要更复杂的定量方法.
研究的目的:
- 开发和验证一个共同的模型,用于预测转移性结直肠癌中的PFS.
- 用基于模型的预测来比较FOLFOX与FOLFOX + panitumumab的疗效.
- 量化治疗响应的个人间变异性 (IIV).
主要方法:
- 构建了一个联合模型,结合了瘤生长抑制和事件概率框架.
- 使用非线性混合效应建模来量化IIV.
- 集成机器学习用于共变量分析,以减少无法解释的IIV.
主要成果:
- 联合模型准确地描述了瘤大小和PFS数据.
- 使用截断和外部数据表现出良好的预测能力.
- 确定了帮助解释IIV的患者共变量.
结论:
- 基于模型的PFS预测是可行的和有价值的.
- 开发的联合模型可以支持临床试验设计和候选药物评估.
- 这种方法为评估瘤学中的组合疗法提供了一种定量方法.
相关概念视频
Cancer Survival Analysis
402
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
402
Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Kaplan-Meier Approach
195
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
195
Tumor Progression
6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
Comparing the Survival Analysis of Two or More Groups
228
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
228
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K


